Drugs / Astegolimab
Astegolimab
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06462118 | Jun → Oct 2024 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02170337 | Jul 2014 → May 2016 | chronic rhinosinusitis | Amgen | Completed | No outcome recorded |
| Phase 25 trials · 2 met primary · 2 missed | ||||||
| Phase 2 | NCT05037929 | Oct 2021 → Feb 2025 | chronic obstructive pulmonary disease | Genentech, Inc. | Completed | Met primary |
| Phase 2 | NCT04386616 | Jun 2020 → Jan 2021 | pneumonia | Genentech, Inc. | Completed | Missed primary |
| Phase 2 | NCT03747575 | Feb 2019 → Mar 2020 | atopic eczema | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03615040 | Oct 2018 → May 2020 | chronic obstructive pulmonary disease | University of Leicester | Completed | Missed primary |
| Phase 2 | NCT02918019 | Sep 2016 → Apr 2019 | asthma | Hoffmann-La Roche | Completed | Met primary |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT05878769 | Jun 2023 → Jul 2034 expected | chronic obstructive pulmonary disease | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT05595642 | Dec 2022 → Jun 2025 overdue | chronic obstructive pulmonary disease | Hoffmann-La Roche | Active not recruiting | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01928368 Comparator | Aug 2013 → Mar 2016 | asthma | Amgen | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-07-24 | Hoffmann-La Roche | Results [Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025 roche.com ↗
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks. |
| 2025-07-21 | Hoffmann-La Roche | Results [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease roche.com ↗
The pivotal phase IIb ALIENTO study met its primary endpoint and showed that astegolimab reduced the annualised exacerbation rate (AER) by a statistically significant 15.4% at 52 weeks, when given every two weeks. |
| 2025-07-20 | Genentech, Inc. | Results Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease gene.com ↗
The pivotal Phase IIb ALIENTO study met its primary endpoint and showed that astegolimab reduced the annualized exacerbation rate (AER) by a statistically significant 15.4% at 52 weeks, when given every two weeks. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-24 | Hoffmann-La Roche | [Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025 roche.com ↗ |
| 2025-07-21 | Hoffmann-La Roche | [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease roche.com ↗ |
| 2025-07-20 | Genentech, Inc. | Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease gene.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | astegolimab | “This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD).” NCT03747575 ↗ |
| Known as | AMG 282 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02170337 ↗ |
| Known as | MSTT1041A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04386616 ↗ |
| Known as | RG-6149 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594385 ↗ |
| Known as | RO-7187807 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594385 ↗ |
| Action | Inhibit | “a human immunoglobulin G2 monoclonal antibody that selectively inhibits the IL-33 receptor, ST2” PMID 36519984 ↗ Nov 2022 |
| Modality | Monoclonal antibody | “a human immunoglobulin G2 monoclonal antibody that selectively inhibits the IL-33 receptor, ST2” PMID 36519984 ↗ Nov 2022 |
| Route | Intravenous | “Single dose either subcutaneously or intravenously on day 1.” NCT01928368 ↗ |
| Route | Subcutaneous | “Single dose either subcutaneously or intravenously on day 1.” NCT01928368 ↗ |